Log In
Print
BCIQ
Print
Print this Print this
 

Toctino, alitretinoin (BAL4079)

  Manage Alerts
Collapse Summary General Information
Company Basilea Pharmaceutica AG
DescriptionVitamin A derived 9-cis retinoic acid
Molecular Target Retinoic acid receptor (RAR)
Mechanism of ActionRetinoic acid receptor (RAR) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDermatitis
Indication DetailsTreat chronic hand dermatitis; Treat severe chronic hand eczema
Regulatory Designation
Partner Almirall S.A.; GlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

0

$226.3M

$77.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today